# Innovative Molecules

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innovative-molecules

- Industry: Biotechnology
- Headquarters: Munich, Germany
- Website: www.innovativemolecules.com
- Total disclosed funding: $24M
- Latest round: Series A (May 28, 2021)
- Investors on record: 1

## About

Innovative Molecules GmbH, based in Munich, Germany, is dedicated to developing advanced therapeutics targeting herpes simplex virus (HSV) infections, with a focus on innovative antiviral solutions.Founded in 2016, Innovative Molecules GmbH specializes in creating therapeutics for HSV infections. The company has not undergone significant strategic pivots since its inception. Thomas Hoffmann, the founder, has been instrumental in steering the company's research and development efforts. Innovative Molecules raised EUR 20.000 mn in Series A funding led by EQT Life Sciences on May 28, 2021, which marks the total amount raised by the company to EUR 20.000 mn, resulting in a current company valuation of EUR 39.819 mn.Innovative Molecules specializes in the development of advanced therapeutics targeting herpes simplex virus (HSV) infections. Its flagship product, IM-250, is an orally available, selective HSV-helicase primase inhibitor that inhibits DNA unwinding, crucial for viral replication. This drug aims to manage recurrent herpes outbreaks and reduce latent HSV reactivation, primarily serving healthcare providers and clinicians throughout Europe, as evidenced by ongoing Phase 1 clinical trials in Germany.The revenue structure of Innovative Molecules is primarily based on the sales of its flagship product, IM-250, within a B2B framework targeting healthcare providers and pharmaceutical distributors. The product is expected to be acquired in bulk by healthcare institutions, establishing a direct revenue channel. Pricing plans reflect the novel therapeutic profile of IM-250, with structured pricing based on purchase volume or contractual agreements, enhancing financial viability and market presence in the antiviral therapeutics sector.Innovative Molecules GmbH plans to utilize the EUR 20.000 mn raised in Series A funding to advance its preclinical products. The company is focused on developing new therapeutics for HSV and aims to expand its market reach into additional European regions following successful regulatory approvals. Ongoing innovations and product advancements are expected to support these growth initiatives.

## Funding rounds

- Series A, May 28, 2021, $24M — EQT Life Sciences

## Investors

- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A